Depression is a chronic, recurring and potentially life-threatening illness that affects up to 20% of the population across the globe.\[[@ref1]\] The etiology of the disease is suboptimal concentrations of the monoamine neurotransmitters serotonin (5-HT) and norepinephrine (NE) in the central nervous system (CNS). It is also due to consequence of dysfunctional endocrine, immune and neurotransmitter systems.\[[@ref2]\]

Depression is a chronic condition.\[[@ref3]\] Primary clinical manifestations of depression are significant depression of mood and impairment of function. Some features of depressive disorders overlap those of the anxiety disorders, including panic-agoraphobia syndrome, severe phobias, generalized anxiety disorder, social anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder.\[[@ref4]\]

Recent advancement in antidepressant therapeutics include the monoamine oxidase inhibitors (MAOIs, e.g. Nardil^®^) tricyclic antidepressants (TCAs, e.g. Elavil). They increases the synaptic concentration of either two (5-HT and NE) or all three (5-HT, NE and dopamine (DA)) neurotransmitters. The combined effect of Serotonin selective reuptake inhibitor (SSRI) (Prozac^®^) and serotonin reuptake transporter (SERT) inhibitor increases synaptic concentration of 5-HT and its duration of action.

Recent studies suggest that combination therapy using bupropion, a Dopamine transporter (DAT) inhibitor, and an SSRI or Serotonin--norepinephrine reuptake inhibitor (SNRI) offers improved efficacy in the treatment of depression compared with monotherapy alone.\[[@ref2]\] For example, DOV-21947 (by DOV pharmaceutical, Phase II), SEP-225289 (by Sepracor, Phase II), and NS-2359 (by NeuroSearch, Phase II).\[[@ref5]\] A new SNRI class of antidepressants (Cymbalta^®^) are also approved to treat depression along with anxiety (approximately 60% of patients).\[[@ref2]\]

The major problems of existing antidepressant drugs include delayed clinical benefit, serious side-effects, and a response in less than 50% of patients.\[[@ref6]\] Neither the pathophysiology of depression nor the mechanism of action of various antidepressant agents is fully understood.\[[@ref7]\] Consequently, there is still a great need for faster-acting, safer, and more effective treatments for depression. In an effort to expand beyond classical monoamine-based strategies, recent medication development activities have focused on neurotrophic factors, glutamatergic systems, and the hypothalamic--pituitary axis (HPA) as well as a number of other less well-characterized novel targets \[[Table 1](#T1){ref-type="table"}\].

###### 

Survey of the pharmacological mechanisms of new accepted antidepressants in clinical development\[[@ref8]\]
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The present review focuses on potent heterocyclic nuclei and derived compounds showing antidepressant activity.\[[@ref6]\]

Indole {#sec1-1}
======

Indole is a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring. Numerous pharmacological active compounds have an indole nucleus such as Tryptophan (essential amino acid), serotonin (neurotransmitter), melatonin (hormone). Indole nucleus shows potent antidepressant activity, various derivatives of indole and 5-HT serve as a template for the development of new chemical entities that act on 5-HT~1A~ receptor and the SERT.\[[@ref9]\] Mattson *et al*.,\[[@ref10]\] synthesized some potent serotonin reuptake inhibitors based on indole nucleus and they reported that compound (12) reveals potent hSERT binding (Ki) 0.18 nM) *in vitro*. Indole nucleus is present in many important classes of therapeutic agents.\[[@ref11]\] Indole alkaloidal analogues and indoles condensed with different heterocycles\[[@ref12]\] showed different biological activities. Idayu *et al*.,\[[@ref13]\] investigated the antidepressant effect of Mitragynine (1) isolated from Mitragyna speciosa Korth. Mitragynin showed potent antidepressant activity at dose of 10 mg/kg and 30 mg/kg i.p. and reduced the immobility time of mice in both Forced swimming test (FST) and Tail suspension test (TST) without any significant effect on locomotor activity in open field test (OFT).

Bispyridyl ethers have indoline nucleus and have selected or potent activity towards CNS disorder. (SB-242084) and (SB-243213) (Phase 1 clinical trials) are bispyridyl ethers having potent 5-HT~2C~ receptor inverse agonistic activity and selective activity for both the 5-HT~2A~ and 5-HT~2B~ receptors. Bromidge *et al*.,\[[@ref14]\] synthesized a series of bisaryl ethers and evaluated their antidepressant activity. Compounds (2), (3) and (4) possess potent activity in the rat hypolocomotion assay.

Shelke *et al*.,\[[@ref15]\] synthesized a series of 2-(5H-\[1, 2, 4\] triazino \[5, 6-b\]indol-3-ylthio)-N-(substituted phenyl) acetamides. Selected compounds were screened for potential antidepressant activity on animal model by tail suspension test (TST) in mice. On the basis of quantitative structure activity relationship (QSAR) study they proved that compounds like (5a), (5n), (5o), (5j) and (5p) have activity compared to standard antidepressant drugs moclobemide, imipramine and fluoxetine.

**Heffernam** *et al*.,\[[@ref16]\] synthesized a series of 4-amino ethyl -3- (phenyl sulfonyl)1-*H* indole(6) and screened the compound for dual-acting norepinephrine reuptake inhibitor and 5-HT~2A~ reuptake antagonist. Compound (6a) and (6b) were potent inhibitors of norepinephrine reuptake and possessed modest h~5~-HT~2A~ antagonist activity. When the amino-ethyl chain shifted from the fourth to fifth and seventh position, it behaved as a potent antagonist.

Manning *et al*.,\[[@ref17]\] synthesized a series of enantiomerically pure 1-naphthyl and 4-indolyl arylalkylamines and evaluated them for binding affinities to the monoamine transporters. They designed (S)-4-(3, 4-dichlorophenyl)-4-(1H-indol-4-yl)-N-methylbutan-1-amine as a potent inhibitor for the dopamine and serotonin transporters. They showed that compounds (7) and (8) have strong binding affinity to DAT and SERT (3.83 and 0.815 nM respectively) and a 1000-fold selectivity compared to the Norepinephrine transporter (NET) binding affinity.

Serotonergic neurotransmission is known to modulate various physiological and behavioral functions in the CNS. It is related to ′integrating′ emotion, cognition, motor function, pain, circadian rhythm and neuroendocrine functions. Ben-Daniel *et al*.,\[[@ref9]\] synthesized a new class of indole derivatives, some potent compounds have low nanomolar affinity for the SERT and high selectivity for 5-HT~1A~ receptor. Six indolylpropylamine derivatives were synthesized and evaluated for SERT inhibitory activity. The most potent compound (9), 2-\[3-(5-fluoro-*1H*-indol-3-yl)-propyl\]-6-methoxy-1, 2, 3, 4-tetrahydro isoquinoline showed promising antidepressant effect and was also evaluated in vivo using positron emission tomography (PET) in animal models.

Brominated indole alkaloids form a common class of metabolites obtained from sponges of the order Verongida. Kochanowska *et al*.,\[[@ref18]\] reported the isolation, structure determination, and activity of metabolites obtained from three Florida sponges, namely Verongula rigida (order Verongida, family Aplysinidae), Smenospongia aurea, and S. cerebriformis (order Dictyoceratida, family Thorectidae). They isolated some compounds among which compound (10) 5, 6-dibromo-N,N-dimethyltryptamine exhibited significant antidepressant activity on rodent FST model.

Selective serotonin reuptake inhibitors (SSRIs) have great success in treating depression and have fewer and less severe side-effects than first-generation drugs. Zhou *et al*.,\[[@ref19]\] reported a series of analogues of arylpiperazine-4-yl-cyclohexylindole (11) evaluated as 5-HT transporter inhibitor and 5-HT~1A~ receptor antagonist.

Liu *et al*.,\[[@ref20]\] reported the tryptamine derivatives for antidepressant activity. They suggested the regiospecific synthesis of a series of 1-sulfonyl azepinoindoles bearing a sulfonyl group at indole N1 position, which showed potent 5-HT~6~ activity. They concluded that rigidified structures of azepino indole derivatives bind effectively to the 5-HT~6~ receptor in a constrained conformational mode. According to the structure activity relationship (SAR) studies, alkyl group is unfavorable to the peptide backbone of the receptor. Selected compounds were evaluated for 5-HT~6~ functional activity. Compound (12) showed promising antidepressant activity with (IC~50~ = 162 nM).

5-Hydroxytryptamine (5-HT, serotonin) is an important neurotransmitter that plays a significant role in a variety of physiological functions in the CNS and peripheral tissues. Deskus *et al*.,\[[@ref21]\] synthesized a series of indole tetrahydropyridine and indole cyclohexenylamines and studied their binding affinities at the human serotonin transporter (SERT). They found out that the nitrile substituent at the C5 position of the indole ring gave potent antidepressant activity through selectivity over SERT. On the basis of modeling studies they conclude that Compound (13a) and especially R-enantiomer reveal selectivity for serotonin transporter IC~50~ (nM) over dopamine and norepinephrine transporters.

Mahaney *et al*.,\[[@ref22]\] designed a variety of 3-(1H-indole-1yl)-3-aryl propan-1amines (14) and evaluated them for dual-acting norepinephrine and serotonin reuptake inhibitors. The antidepressant effect of compound (14) was found to be promising.

Evrard *et al*.,\[[@ref23]\] synthesized some derivatives of serotonin reuptake inhibitor 4-(5-fluoro-*1H* indol-3-yl)cyclohexylamine and evaluated them for antidepressant activity. Compounds containing 1-(4-indolyl)piperazine and 2-(1H-indol-4-yloxy)ethylamine showed promising activity. They identify 4-(5-fluoro-1H-indol-3-yl) cyclohexylamine as a more optimized template for the design of dual-acting SSRI/5-HT~1A~ antagonists. Compound (15) possessed potent and balanced affinities for the two molecular targets and exhibited potent antidepressant activity.

The serotonin (5-HT) receptors have been divided into seven subclasses (5-HT~1-7~). Numerous antidepressants and antipsychotic drugs have high affinity for the 5-HT~6~ receptor. Cole *et al*.,\[[@ref24]\] synthesized a series of N1-arylsulfonyl-3-(1, 2, 3, 6-tetrahydropyridin-4-yl)indole derivatives. Some synthesized compounds were shown to have high affinity for the 5-HT~6~ receptor. Two analogs, 4-\[3-(1, 2, 3, 6-tetrahydropyridin-4-yl)-*1H*-indole-1-sulfonyl\]- phenyl amine (16a) and 4-\[3-(1, 2, 3, 6-tetrahydropyridin-4-yl)-5-methoxy-1H-indole-1 sulfonyl\]-phenylamine (16b), have 0.4 and 3.0nM affinity, and antagonized the production of adenylate cyclase at sub-nanomolar concentrations.

Simple homotryptamines are potential SSRIs. Schmitz *et al*.,\[[@ref25]\] synthesized a series of N,N dimethylhomotryptamines and binding affinities of the synthesized compounds were determined by using HEK-293 cells that stably expressed human serotonin transporters (HEK-hSERT cells). They also revealed that compounds possessing an electron withdrawing substituent at the C5 position of the indole nucleus are potent SSRIs. From the synthesized compounds 5-cyano homotryptamine (17) was the most potent compound with (IC~50~ = 2 nM).

Tryptamine and isotryptamine are compounds having indole nucleus. Kolanos *et al*.,\[[@ref26]\] studied the binding affinity of indolic nitrogen for h5-HT~6~ serotonin receptors. They concluded that indolic nitrogen atom is essential for the binding of N1-benzyltryptamines at h5-HT~6~ serotonin receptors.

The serotonergic (5-HT) system is a key target for antidepressant drugs; human serotonin transporter (hSERT) is one of the major regulators of synaptic 5-HT levels. Mattson *et al*.,\[[@ref10]\] synthesized a series of indole cyclopropylmethylamines and some selected synthesized compounds were evaluated for antidepressant activity. On the basis of structure activity relationship, Nitrile substituents at the 5 and 7 positions of the indole ring gave high affinity for hSERT, while N-1 Substitution in indole ring with methyl or ethyl group decreases in 10- to 30-fold affinity for hSERT. Compound (+)-(19) demonstrated potent hSERT binding (K~i~) 0.18 nM) *in vitro* and was more than 1000-fold less potent at hDAT, hNET, 5-HT~1A~, and 5-HT~6~. The maximal response of this compound was similar to that of fluoxetine.

Heinrich *et al*.,\[[@ref27]\] synthesized derivatives of 5-cyano-6-hydroxy-1*H*-indole, which is a major metabolite of the potential antidepressant drug Vilazodone. Compounds (20a) and (20b), evaluated for antidepressant activity showed an innovative dual mechanism at the 5-HT~1A~ receptor.

Mewshow *et al*.,\[[@ref28]\] designed and synthesized a novel series of indole derivatives (21) and evaluated them for dual 5-HT transporter reuptake and 5-HT~1A~ antagonist activity. Compound (21a) showed much higher 5-HT~1A~ and 5-HT transporter affinity.

Meagher *et al*.,\[[@ref29]\] reported a set of indonyl cylohexylamine (22). The synthesized compounds were evaluated for potent and selective serotonin reuptake inhibition. Substitution at the indole fifth position with cyano (22a) and fluoro (22b) led to an improvement in 5-HT transporter affinity.

Serotonin (5-HT) is a biogenic amine neurotransmitter; antidepressant effect of the selective 5-HT reuptake inhibitors (SSRIs) is due to enhancement of postsynaptic 5-HT levels. Matzen *et al*.,\[[@ref30]\] prepared a series of unsymmetrical ureas and evaluated them as 5-HT reuptake inhibitors with 5-HT~1B/1D~ antagonistic activities. For the designing of the compounds, they coupled the various indole derivatives (inhibit 5-HT reuptake), with three different aniline moieties (5-HT~1B/1D~ ligands). Compound no. (23) (4-(5-fluoro-*1H*-indol-3-yl)piperidine-1-carboxylic acid \[4-methoxy-3-(4-methylpiperazin-1-yl) phenyl\] amide), (23a), and (23b) showed the most potent antidepressant activity through 5-HT reuptake inhibition and 5-HT~1B/1D~ antagonism *in vitro* using rabbit saphenous vein model and 5-HT release from guinea pig cortical slices.

Primofiore *et al*.,\[[@ref31]\] synthesized a range of *N*-(indole-3-ylgloxyl) (24) dopamine derivatives. All products were evaluated for their antidepressant activity. The *N*-(5-chloro indole-3-ylgloxylyl) dopamine (24a) proved to be of particular interest and exhibited good activity.

Ergence *et al*.,\[[@ref32]\] synthesized a series of arylidenehydrazides (25) by reacting 3- phenyl-5-sulfonamidoindol-2- carboxylic acid hydrzide with various aldehydes and evaluated them for antidepressant activity by Porsolt\'s forced swim method by using tranylcypromine as standard drug. Compound 3-phenyl -5-sulfonamidomindol-2-corboxylic acid, 3, 4- methylene dioxybenzylidene hydrazide (25a), 3-phenyl-5-sulfonamidoindole-2-carboxylic acid 4-methylbenzylidene hydrazide (25b), 3-phenyl-5-sulfonamidoindole-2-carboxylic acid 4-nitrobenzylidene hydrazide (25c), 3-phenyl-5-sulfonamidoindole-2-corboxylic acid benzylidene hydrazide (25d), showed antidepressant activity at 100 mg/kg.

Thiadiazole {#sec1-2}
===========

The thiadiazole system is a cyclic analogue of thiosemicarbazide having the toxophoric N=C=S linkage.\[[@ref33]\] Thiadiazole is derived from thiophene by replacing two -CH= group by pyridine-type nitrogen (-N=) and is found in four isomeric forms depending on the relative positions of nitrogen atoms. A number of synthetic products have been framed on the basis of thiadiazole nucleus which show broad range of biological activities, for example, the thiadiazole SCH-202676 is a promising allosteric modulator of G-protein coupled receptors-4, KC12291 showed cardioprotective action, and small heterocyclic thiadiazolidinones (TDZD) are first non-ATP competitive glycogen synthase kinase 3b inhibitors.\[[@ref34]\] Thiadiazole derivative compounds displayed potent antidepressant and anxiolytic activity. Clerici *et al*.,\[[@ref35]\] synthesized some potent compounds based on 2-amino-5-sulfanyl-1, 3, 4-thiadiazole and evaluated them for CNS activity. Compound (26) exhibited marked antidepressant activity.\[[@ref36]\]

Yusuf *et al*.,\[[@ref37]\] synthesized a series of new imine derivatives of 5-amino-1,2,3-thiadiazole 2-thiol. Antidepressant activity was tested against imipramine as reference drug using FST in mice. Compound (27a) 5-{\[1-(4-chlorophenyl)-3-(4-methoxyphenyl)prop-2-ene-1ylidine\]-amino\]-5-benzyl thio-1,3,4-thiadiazole, and compound (27b) 3-{\[1-(chloropheny)-3-(4-dimethyl-amino phenyl)-prop-2ene1-ylidine\]amino)-5-benzylthio-1,3,4-thiadiazole showed significant antidepressant activity. Compound (27a) and (27b) decreased immobility time by 77.99% and 76.26% compared to the standard imipramine (82%).

Pathanayk *et al*.,\[[@ref38]\] synthesized novel 2-amino-5-sulfanyl1, 3, 4 thaidiazole analogues (28). Potentially active analogues (28a), (28b) and (28c) characterized by spectral analysis and evaluated for antidepressant activity exhibited promising antidepressant activity in pharmacological models and in also comparison with reference antidepressant drugs.

Sharma *et al*.,\[[@ref39]\] worked on a compound 2-amino-5-sulfanyl 1, 3, 4-thiadiazole(29) and synthesized a new series of compounds (29a), (29b), (29c), (29d), (29e) .The newly synthesized compounds were characterized by analytical and spectral methods. Compounds (29d), (29e), (29f), (29g), (29h) exhibited significant antidepressant activity in comparison to the reference drugs.

Varvarsou *et al*.,\[[@ref40]\] synthesized a series of *N*-5-(2 methyl-1*H*-3-indolyl) melhyl)-1, 3, 4-thiadiazol-2-yl-*N*-arylamine. Compounds (30a and 30b) were evaluated for antidepressant activity by forced swim test using imipramine as standard drug.

Jatav *et al*.,\[[@ref41]\] synthesized a series of 3-\[5-substituted phenyl-1, 3, 4-thiadiazole-2-yl\]-2-styryl quinazoline-4(*3H*)-ones. Out of 18 synthesized compounds, compound no (31) exhibited potent antidepressant activity through forced swim test method.

Piperidine {#sec1-3}
==========

Piperidine ring is an omnipresent molecular skeleton. A large number of piperidine-containing compounds are biologically and medicinally important. Biological properties of piperidines are highly dependent on the type and location of substituents on the heterocyclic ring.\[[@ref42]\] Various N-heterocyclic piperidine compounds have been mentioned in clinical and preclinical studies.\[[@ref43]\] Piperidine nucleus occurs in active pharmacological substances, for example Eliprodil (SL-82.0715) (N-Methyl-D-aspartic acid (NMDA) antagonist).\[[@ref44]\]

Takeuchi *et al*.,\[[@ref45]\] synthesized a series of 1-(*1H*-indol-4- yloxy)-3-(4-benzo\[b\]thiophen-2-ylpiperidinyl) propan-2-ols and evaluated them for antidepressant activity. They identified some fused bicyclic aryl-substituted piperidines as an essential pharmacophore for 5-HT reuptake inhibition and also having potent dual 5-HT~1A~ receptor antagonism and serotonin reuptake inhibition. On the basis of potency and activity compound (32) showed combined 5-HT~1A~/SSRI activity in a single molecule with no negative feedback effect.

Bollinger *et al*.,\[[@ref46]\] synthesized 1, 4-disubstituted aromatic piperidines and piperazines (1,4-DAPs) and showed the effect of some synthesized compounds on endogenous neurotransmitters including dopamine, serotonin, and (nor)epinephrine. Compound (33) reported to be a potent agonist for 5HT~1A~ receptor and showed promising antidepressant effect having K~i~ value of 2.7 nM and a maximal efficacy of 124%.

Boot *et al*.,\[[@ref47]\] reported a set of *N*-alkyl-N-arymethylpiperidin-4-amines (34a) and derivatives were demonstrated to be inhibitors of both serotonin and norepinephrin reuptake. 4- Fluro-2-trifluoromethyl substitution (34b) pattern was evaluated for optimization towards dual SERT and NET inhibition.

Rocco *et al*.,\[[@ref48]\] designed a series of 1-(1*H* indole-4-yloxy)-3-(4-aryl pipridinyl)propan-2-ols (35a). Compound (35b) was found to be a potent dual 5-HT~1A~ receptor antagonist and serotonin reuptake inhibitor.

Steckler *et al*.,\[[@ref49]\] designed a set of derivatives of 4-phenyl-4-\[1*H*-imidazole-2-yl\]-piperidine (36). Compound (36a) acted as a selective non-peptide delta opoid agonist with antidepressant and anxiolytic activity.

Trabanco *et al*.,\[[@ref50]\] synthesized 4-phenyl-4-(1*H*-imidazol-2-yl) Piperidine derivatives (37) and evaluated their antidepressant-like effect by mouse tail suspension test. Compound (37a), (37b) stand as the most potent compounds prepared within this series.

Ahmed *et al*.,\[[@ref51]\] synthesized several benzhydroxylalkylpiperidine derivatives (38) and evaluated them by pharmacological tests for antagonism of reserpine and apomorphine-induced hypothermia. Compounds were evaluated by tail suspension test in mice. Preferred compounds were also studied pharmacologically by binding study to serotonin (5HT), norepinephrine (Ne) and dopamine (DA) reuptake site and showed antidepressant activity.

Takeuchi *et al*.,\[[@ref52]\] synthesized a series of 1-aryloxy-3-piperidinylpropan-2-ols having potent dual 5-HT~1A~ receptor antagonism and serotonin reuptake inhibition. They also proposed some beneficial modification of potential metabolic sites of 1-(1*H*-indol-4-yloxy)-3-(4-benzo\[b\]thiophen-2-ylpiperidinyl) propan-2-ols, which is essential for improved *in vitro* binding affinities and functional antagonism over 5HT~1A~ receptor and 5-HT reuptake sites. The most potent compound identified was (39).

Takeuchi *et al*.,\[[@ref53]\] synthesized a series of 1-(1*H*-indol-4-yloxy)-3-(4-benzo\[b\]thiophen-2-ylpiperidinyl) propan-2-ols. Some potent derivatives showed 5-HT~1A~/SSRIs activity at low nanomolar and subnanomolar concentrations. They found that incorporation of the α-methyl group in the piperidine ring with its specific stereochemistry enhanced binding affinity at the 5-HT reuptake site and also *in vitro* 5-HT~1A~ antagonist functional activity. Compound (40) and the exo-isomer showed potent antidepressant activity.

Ong *et al*.,\[[@ref54]\] synthesized a series of l-arylspiro\[indoline-3,4′-piperidines\] and some potent compounds were evaluated for potential antidepressant activity in the reference of tetrabenazine (TBZ) ptosis prevention and potentiation of 5-hydroxytryptophan (5-HT~P~)-induced head twitching in pargyline-pretreated rats. Compound (41) showed potent *in vitro* antidepressant activity.

Many drugs showed antidepressant effect by interacting with σ receptors present in brain regions. Wang *et al*.,\[[@ref55]\] studied two novel σ receptor agonists UMB23 (1-(3-phenylpropyl) piperidine oxalate) (42), UMB82 (2-(3,4-dichlorophenyl)-N-ethyl-N-(2-piperidin-1-ylethyl)ethanamine oxalate) (43) and evaluated them for antidepressant-like activity in mice through two standard methods, first radio ligand binding studies and second the forced swim test. Compound UMB23 precisely displayed a high degree of selectivity, showing Nano molar affinities for each of the σ receptor subtypes. They also reveal that σ receptor antagonist BD1047 attenuated the antidepressant-like effects of UMB23 and UMB82.

Balsamo *et al*.,\[[@ref56]\] synthesized a series of 3-\[1-(2-ethoxyphenoxy)methyl\] piperidine derivatives. They screened some potential antidepressant compounds through reserpine interaction test in mice and evaluated them for reuptake inhibition of biogenic amines in pig brain synaptosomal fractions. On the basis of *in vivo* and *in vitro* tests they revealed that compound (44a) and (44b) have antidepressant activity comparable to that of reference antidepressant drug viloxazine.

He *et al*.,\[[@ref57]\] synthesized a series of 4-(4-Chlorophenyl) piperidine derivatives having a thioacetamide side chain and evaluated them for potent antidepressant activity through dopamine transporter/norepinephrine transporter (DAT/NET) selectivity. They concluded that compounds (-)-trans-(45a), (+)-cis-(45b), and (-)-cis(45c) show fairly good potency, the K~i~ value of (+)-cis-(45b) at the NET is 5.5 nM and showed best selectivity for the NET.

Orjales *et al*.,\[[@ref58]\] prepared a series of \[aryl(aryloxy)methyl\] piperidine derivatives and selected synthesized compounds were evaluated for antidepressant activity. These compounds had high affinity for serotonin (5-HT) transporter (SERT), 5-HT~1A~ and 5-HT~2A~ receptors and also Norepinephrine (NE) transporters and linked directly or through a methylene chain to different substituted and unsubstituted nuclei (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane) for potentiation of antidepressant effect. They reported that Compound (-)-(46) (coded as F-98214-TA) possess a dual binding character and very high affinity value for SERT and NET (Ki)1.9 and 13.5 nM, respectively from rat brain using radioligand binding assay.

Vacher *et al*.,\[[@ref59]\] prepared a series of aryl-{\[4-(6-R-pyridin-2-ylmethyl)-amino\]-methyl}- piperidin-1-yl-methanone as 5-HT~1A~ receptor agonists. They reported that the fluorine atom at the C4 position of the piperidine ring enhances the oral bioavailability and 5-HT~1A~ agonist activity in rats. Some potent derivatives (47), (48), and (49) have higher affinity and selectivity to 5-HT~1A~ receptors. For comparing the conformation of the pharmacophore and agonistic activity they synthesized a series of 3-chloro-4-fluorophenyl-(4- fluoro-4{\[(5-(H or CH~3~)-6-R-pyridin-2-ylmethyl)-amino\]-methyl}-piperidin-1-yl-methanone derivatives. They concluded that compounds (50), (51), and (52) have potent antidepressant activity measured through forced swimming test (FST) in rats.

Gray *et al*.,\[[@ref60]\] synthesized a series of aryl piperazine and piperidine ethers and selected compounds were evaluated for antidepressant activity through both norepinephrine reuptake inhibitors (NRI) and 5-HT~1A~ partial agonist effect. They concluded that compounds (53) and (54) are the most promising and potent for antidepressant activity. Compounds (54) in 10 mg/kg subcutaneous injection, penetrates into the brain and binds to both target receptors in Sprauge-Dawley rats.

Piperazine {#sec2-1}
----------

Piperazine is a six-membered heterocyclic ring having two opposing nitrogen atoms. the piperazine nucleus has potent antidepressant activity. Various derivatives of piperazine show potent serotonin antagonist/reuptake inhibitors, YM-992, LY367265, Nefazodone and Aripiprazole are the typical examples.\[[@ref61]\] WAY-100635 is a 5-HT~1A~ receptor antagonist.\[[@ref62]\] 1-(2-Pyrimidinyl)-piperazine is a major active metabolite of tandospirone, gepirone, ipsapirone, and buspirone which also have antidepressant/anxiolytic 5-HT~1A~ agonists′ activity.\[[@ref63]\] The pharmaceutical importance of this nucleus is due to extensive occurrence in current marketed drug.\[[@ref64]\] Various antidepressant drugs have a piperazine nucleus such as Amoxapine, Befuraline, Binospirone, Alnespirone, Buspirone, Flesinoxan, Gepirone, Ipsapirone, Nefazodone, Piberaline, and Tandospirone. Arylpiperazine moiety is used as a template for designing CNS-active agents. It constitutes the main pharmacophoric fragment, for serotonergic, dopaminergic, and adrenergic receptors.\[[@ref65]\]

Fray *et al*.,\[[@ref66]\] synthesized a new class of dual serotonin noradrenalin reuptake inhibitor *N*-(1,2-diphenylethyl) piperazine (55). Two compounds possessed comparable *in vitro* profile to the dual reuptake inhibitor duloxetine. *N*-substituted piperazine (55a) potently inhibited both \[3H\]-5HT and \[3H\]-NA reuptake in HEK 293 cell transfected with human amine transporter with 100-fold selectivity over the DA transporter.

Kang *et al*.,\[[@ref67]\] synthesized aryl piperzine containing pyrrole-3-carboxamide derivatives (56). These derivatives were evaluated for binding to 5HT~2A~, 5-HT~2C~ receptor and 5-HT transporter. Compound (56a) showed good efficacy. Antidepressant activity of interesting compounds was evaluated by FST on mice using fluoxetine as reference drug. Compound (56b) proved to be the most potent.

**Kling** *et al*.,\[[@ref68]\] synthesized 2- methoxy arylpiperazine (57) series based on the *N*-4-aryl-piperazinyl-*N*-ethyl-5, 6, 7, 8-tetrahydropyrido \[4,3,4.5\] thieno (2,3-d) pyrimidine-4(3*H*)-one core. Isoquinoline analogue (57a) displayed high affinity and an antagonistic mode of action for the 5-HT~1A~ and the 5-HT~1B~ receptors. Compound (57a) was shown to increase \[3*H*\] 5-HT release from rat brain cortical slices.

Torrado *et al*.,\[[@ref69]\] synthesized a series of compounds combining the naphthylpiperazine (58) and thienopyran scaffolds and evaluated for 5-HT reuptake inhibitor with 5-HT~1D~ antagonist activity. The designed compound (59) has been based on the ′overlapping type strategy where two pharmacophores (58) and thinopyran are linked in a single molecule, the resultant compound (59) has a dual pharmacological profile and has the potential to deliver a more efficient treatment for depression. Analogue (59a) chloro substituted at C~3~ position of the theopyran showed the most promising profile.

Zajdel *et al*.,\[[@ref70]\] synthesized compound bearing (3-arylamino) pyrrolidine-2,5-dione (60) and *N*-arylprolinamide (61) moieties showing high affinity for 5-HT~1A~, high to low for 5-HT~2A~ and low for D~2~ receptor. Compounds (60a) and (60b) were found to be 5-HT~1A~ partial agonist and compound (60c) was a mixed 5-HT~1A~ antagonist.

Paluchowska *et al*.,\[[@ref71]\] reported some potent flexible and rigid imides with 1-(m-trifluorophenyl)piperazine fragment showing very high affinity (K~i~ = 0.3-34 nM) for 5-HT~1A~ receptors. They screened some potent compounds having antidepressant-like activity in the swim tests in mice. Compounds (62a), (62b) and (62c) showed potent antidepressant effect, greater than that induced by imipramine as a reference antidepressant.

5-HT~7~ receptor belongs to G protein-coupled receptor (GPCRs) and most recently discovered, found in the thalamus, hypothalamus, brainstem, and hippocampus in the brain, and blood vessels in the periphery. SB-269970 a 5-HT~7~ receptor antagonist having piperazine nucleus, exhibited the maximum affinity and the greatest selectivity. Yoon *et al*.,\[[@ref72]\] synthesized a series of 4-methoxy-N-\[3-(4-substituted phenyl-piperazine-1-yl) propyl\] benzene sulfonamides and N-\[3-(4-substituted phenyl-piperazine-1-yl) propyl\] naphthyl sulphonamides and evaluated them for 5-HT~7~ receptor antagonistic activity. The synthesized compound (63) showed a noble activity on 5-HT~7~ receptors and good selectivity on 5-HT~1a~, 5-HT~2a~, 5-HT~2c~, and 5-HT~6~ receptors.

Wu *et al*.,\[[@ref73]\] synthesized and reported a novel series of arylpiperazine derivatives of diphenylsulfide and evaluated them for dual 5- HT~1A~/SSRI activities. They concluded that 2-methoxyphenyl-piperazine moiety is essential for 5-HT~1A~ affinity. Compound (64) of this series showed best antidepressant activity.

Weng *et al*.,\[[@ref74]\] synthesized four optical isomers of SIPI5056 (2-(4-benzylpiperazin-1-yl) 1-(5-chloro-6-methoxynaphthalen-2-yl) propan-1-ol) and evaluated them for antidepressant activities and acute toxicities as novel reuptake inhibitors of monoamine transmitters. They studied two optical isomers (1S, 2R) and (1R, 2S) which have difference in activity and safety. The ED~50~ values of four isomers were measured through single oral dosing mouse tail suspension test (TST) and mouse forced swimming test (FST). They concluded that ED~50~ value of (1R, 2S) isomer was 12.6 mg/kg and (1S, 2R) isomer was 16.5 mg/kg. Isomer (1R,2S)-SIPI5056 is most potent for antidepressant activity.

Abou-Gharbia *et al*.,\[[@ref75]\] synthesized novel adamantyl aryl- and heteroarylpiperazine derivatives and evaluated them for serotonin receptor activities. They reported that the compound (66a) (WY-50,324, SEB-324, adatanserin), adamantyl-1-carboxylic acid 2-\[4-(2-pyrimidinyl)- 1-piperazinyl\]ethylamide, and (66b), adamantyl-1-carboxylic acid 2-\[4-(2-methoxyphenyl)- 1-piperazinyl\]ethylamide, revealed high affinity for 5-HT~1A~ (K~i~) (1nM for both) and also moderate affinity for 5-HT~2~ receptors (K~i~) (73 and 75 nM, respectively). Partial agonistic activity for 5-HT~1A~ was measured *in vivo* in rat serotonin syndrome and 5-HT~2~ antagonist activity in quipazine- and DOI-induced head shakes paradigms. On the basis of animal model results, they confirmed that compound (66a) showed combined anxiolytic and antidepressant activity.

Jorand-Lebrun *et al*.,\[[@ref76]\] reported a series of arylpiperazide derivatives of 1- naphthylpiperazine (1-NP) and evaluate them for 5-HT~1B~ antagonists as potent antidepressant compounds. They observed that arylpiperazide at 7 positions of 1-NP increases the selectivity for 5-HT~1B/1D~ receptor. From the synthesized compounds 2-\[\[8-(4-methylpiperazin-1-yl)naphthalen-2-yl\]oxy\]-1-(4-o-tolylpiperazin-1-yl) ethanone (67) was identified as a potent 5-HT~1B~ antagonist and has a capability to antagonize the inhibition of 5-HT release induced by 5-CT (5-carbamoyltryptamine) in guinea pig hypothalamus slices and also antagonizes the hypothermia induced by selective 5-HT~1B/1D~ agonist *in vivo* in the guinea pig following oral administration (ED~50~ = 0.13 mg/kg).

Mahaney *et al*.,\[[@ref77]\] discovered a series of piperazine-containing analogues for norepinephrine reuptake inhibitors (NRIs) in animal models. On the basis of substitution pattern and animal testing profile, compound (68) (S)-(-)-(WAY-256805) was found to be a potent norepinephrine reuptake inhibitor (IC~50~ = 82 nM and Ki = 50 nM) and showed excellent selectivity over both the serotonin and dopamine transporters. Its antidepressant-like effects were also measured in the mouse tail suspension model.

Quinoline {#sec1-4}
=========

Quinoline is a stable high-boiling liquid with a sweetish odor and is alkaloidal in nature, having a fused benzene and pyridine ring. OPC-14523 (OPC; \[1-\[3-\[4-(3-Chlorophenyl)-1-piperazinyl\] propyl\]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate)\] is a novel compound with high affinity for σ and 5-HT~1A~ receptors as well as for the 5-HT transporter.\[[@ref78]\] Kynuramine has antidepressant activity, bearing quinoline nucleus.\[[@ref79]\] Protoberbines and 8-Oxoberbines are known for antileukemic, antitumor and anticancer activity.\[[@ref80]\] 2′-quinidinone and 3-hydroxy-quinidine, an active metabolite of quinoline ring is also used in cardiac drug therapy.\[[@ref81]\] Oshiro *et al*., synthesized prototypic tricyclic antidepressant, 10,11-dihydro- N,N-dimethyl-*5H*-dibenz\[b,f\]azepine-5-propanamine (imipramine) which showed antidepressant activity by inhibiting the presynaptic reuptake of monoamines, especially 4-(2-amino-1-hydroxyethyl)-1,2- benzenediol (norepinephrine) and 5-hydroxytryptamine (serotonine, 5-HT).\[[@ref82]\]

Beadle *et al*.,\[[@ref83]\] developed a novel series of 1-aryl-3,4-dihydro-1H-quinolin-2-one (69). Analogues of compound (69a), (69b), (69c) were reported as potent and selective norepinephrine reuptake inhibitors.

Tran *et al*.,\[[@ref84]\] developed an antidepressant compound 2,3-dihydro 1,4-dioxino (2,3-f) quinoline (70). Compound (70a) is a derivative of azahetrocyclomethyl. Compound (70a) was evaluated as an antidepressant agent.

Horchler *et al*.,\[[@ref85]\] synthesized 6-methoxy-8-amino-4oxo-1,4-dihydro-quinolin-2-carboxylic acid(-4-morpholin-4yl-phenyl)amides (71a) and 4-amino-6-methoxy-8-(-4-methyl-piperazin-1-yl)-quinoline-2-carboxylic and (4-morpholin-4yl-phenyl)amides (71b). Compound AR-A000002 (72), a selective 5- HT~1B~ antagonist has been shown to have potential as both an antidepressive and an anxiolytic agent.

Ward *et al*.,\[[@ref86]\] prepared some novel derivatives of (SB-649915) 6-((1-(2-(2-methylquinolin-5-yloxy)ethyl)piperidin-4-yl)methyl)-2H-benzo\[b\]\[1,4\]oxazin-3(*4H*)-one as potent, selective 5-HT~1~ receptor antagonists. They reported that molecules with pK~i~ \> 8 against the 5-HT~1A~, 5-HT~1B~, and 5-HT~1D~ receptors have prominently low intrinsic activity and good selectivity towards serotonin transporter (SERT) and are also free of the side-effects associated with the SSRIs. On the basis of SAR, they modified the structure of (SB-649915) and formed (SB-714786) (8-((4-(2-(2-methylquinolin-5-yloxy) ethyl) piperazin-1-yl) methyl) quinolone) which is a selective 5-HT~1D~ receptor antagonist. Compound no. (73) showed potent antidepressant profile acting as a 5-HT~1B~ antagonist *in vivo*.

Kumar *et al*.,\[[@ref87]\] prepared a new series of N-\[(2-chloro-8-methylquinolin-3-yl)methyl\]-(substituted)-aniline / butylamine / cyclohexylamine / benzylamine derivatives. The antidepressant activity of the synthesized compounds was evaluated by FST in rats and their neurotoxicity was evaluated by the rotarod test. Test compounds and clomipramine were administered intraperitoneally at a dose of 100 mg/kg and 20 mg/kg respectively. Preliminary antidepressant screening of compounds revealed that compound (74) significantly (*P*\<0.01) reduces the duration of immobility time.

Pyrazoline {#sec1-5}
==========

Pyrazoline is characterized by a five-membered heterocyclic ring structure. Pyrazolines represent an important class of heterocycles due to their highly pronounced biological and pharmacological activities.\[[@ref88]\]

Siddiqui *et al*.,\[[@ref89]\] designed and synthesized a set of derivatives of N,3-(substituted diphenyl)-5- phenyl-1*H*-pyrazoline-2-carbothioamide(75). Two compounds (75a) and (75b) significantly reduced the duration of the immobility time at a 25 mg/kg dose, when compared to control.

Palaska *et al*.,\[[@ref90]\] synthesized a series of ten new 3, 5-diphenyl-2-pyrazoline derivatives (76). The antidepressant activities of these compounds were evaluated by the Porsolt\'s behavioral despair test on Swiss-Webster mice. Compounds (76a), (76b) and (76c) reduced 41.94-48.62% immobility time at 100 mg/kg dose level. It was found that 4-methoxy derivative (76a) and 4-chloro derivative (76b) on the phenyl ring at 3 of the pyrazoline ring increased the antidepressant activity.

Ozdemir *et al*.,\[[@ref91]\] synthesized 12 1-phenyl,1-thiocarbomoyl and 1-N substituted thiocarbomoyl(-3-(2-furyl)-5-phenyl (77a) or (2-furyl)-2-pyrazoline (77b) derivatives. Compounds (77c) and (77d) reduce 33.80-31.42% duration of immobility times at 10 mg/kg dose level. The antidepressant activities of the compounds were investigated by Porsolt\'s behavioral despair (forced swim) test on albino mice.

Can *et al*.,\[[@ref92]\] synthesized a series of some 1, 3, 5-trisubstituted-2-pyrazoline derivatives (78) and evaluated for antidepressant activity in modified forced swim test. Compound pyrazoline--benzoxazole derivative (78a) and pyrazoline-benzimidazole derivative (78b) showed significant antidepressant activity.

Gok *et al*.,\[[@ref93]\] synthesized 1-\[(*N*,*N*-disubstituted thiocorbamoylthio)acetyl\]-3-(2-thienyl)-5 aryl-2-pyrazolines (79) and evaluated for antidepressant activity by FST. Compounds (79a), (79b), and (79c) significantly shortened immobility time compared to control. Compound (79a) was found to be more effective in FST than clomipramine and tranylcypromine used as reference drugs.

Antidepressants and anticonvulsants are the most beneficial drugs for the treatment of CNS disorders. The pyrazole structure possesses a broad spectrum of biological activities. Abdel-Aziz *et al*.,\[[@ref94]\] synthesized some novel pyrazole derivatives and evaluated them for antidepressant activity. They prepared a series of diacylhydrazines and 5-amino-1-substiuted pyrazole-3, 3, 4-tricarbonitriles by reaction of substituted carboxylic acid hydrazides with ethenetetracarbonitril in presence of dimethyl formamide. Some potent compounds which are derivative of pyrazole (80a) and (80b) show great antidepressant activity compared to imipramine at 10 mg/kg dose level.

Pyrrolidine {#sec1-6}
===========

Numerous substances have this nucleus, for example PF-877423 has established potent *in vitro* activity against both human and mouse 11b-HSD1 enzymes.\[[@ref95]\] Spiro\[9, 10- dihydro-anthracene\]-9,30-pyrrolidine (SpAMDA) have high affinity as 5-HT2A antagonists,\[[@ref96]\] Sulfonamide hydroxamate CGS-27023A as potent MMP inhibitors,\[[@ref97]\] R121919 as CRF-1 receptor antagonists, used in treatment of depression.\[[@ref98]\] AHR-1118 is a pyrrolidine derivative with clinically established antidepressant efficacy.\[[@ref99]\] (+/-)-(1′R∗,3R∗)-3-phenyl-1-\[(1′,2′,3′,4′-tetrahydro-5′,6′-methylene-dioxy-1′-naphthalenyl)methyl\]pyrrolidine methane sulfonate (ABT-200) antagonized the uptake of \[3H\]-norepinephrine into synaptosomes of rat hypothalamus (IC50 = 841 nM).\[[@ref100]\] Rolipram is a PDE4-inhibitor and is being studied as a possible alternative to current antidepressant treatment.\[[@ref101]\]

Bannwart *et al*.,\[[@ref102]\] designed a series of 3,3-disubstituted pyrrolidine derivatives (81). Synthesized compounds were evaluated as monomaine triple reuptake inhibitors. It showed *in vivo* antidepressant-like effect in the mouse tail suspension assay with a minimum effective dose of 30 mg/kg; i.p. The first compound (81a) revels potent inhibitor activity.

Lucas *et al*.,\[[@ref2]\] synthesized two new series of monoamine triple reuptake inhibitors (TRIS) through scaffold homologation of recently reported series of 3, 3-disubstituted pyrrolidine (82) TRIS. The region isomeric 2 and 3 ketopyrrolidine (82a) has a high level of potency against all three monoamine transporters as well as has good human *in vitro* stability.

Zelle *et al*.,\[[@ref103]\] synthesized a novel compound ABT-200(+), (1^1^R∗-3R∗)-3-phenyl-1\[(1^1^,2^1^,3^1^,4^1^- tetrahydro-5^1^,6^1^-methylene-dioxy-1^1^-napthalanyl) methyl\] pyrrolidine (83) which was the first example of a new structural class of potent α- antagonists, which possesses the additional property of nor-epinephrine reuptake inhibitor. The compound was evaluated for antidepressant activity and expected to have utility in the treatment of depression.

Imidazole {#sec2-2}
---------

Imidazole is a five-membered heterocyclic system with three carbons and two nitrogen atoms, at Position 1 is pyrrole type and at Position 2 is pyridine type. Imidazole exists in three partially reduced forms, 2-imidazoline, 3-imidazoline and 4-imidazoline. Imidazole analogues show potent antidepressant activity. Hadizadeh *et al*.,\[[@ref104]\] synthesized some moclobemide derivatives and evaluated them for antidepressant activity. Phenyl ring of moclobemide was replaced by substituted imidazoles, and N-\[(4-morpholinyl)ethyl)\]-1-benzyl-2-(alkkylthio)-1H-imidazole-5-carboxamides (7a-c) were formed. Antidepressant activity was evaluated by FST in mice. Some synthesized compounds were found to be more potent than moclobemide.

Hadizadeh *et al*.,\[[@ref104]\] synthesized *N*-\[(4-morpholinyl)ethyl)\]-1-benzyl-2-(alkylthio)-1*H*-imidazole-5-carboxamide (84) and evaluated it as antidepressant agent using FST in mice. The investigation demonstrated that analogues (84a), (84b) and (84c) are more potent than moclobemide (85) in FST model. Replacement of electron-deficient 4-chlorophenyl in moclobemide (85) with substituted electron-deficient ring imidazole on analogues (84a), (84b), (84c) increases antidepressant potency and also toxicity.

Czopek *et al*,.\[[@ref105]\] synthesized 5-cycloalkyl-5-phenyl and 5-spiroimidazoline-2, 4-dione derivatives with an arylpiperazinyl moiety (86). Compounds showed high affinity for 5-HT~1A~ receptors as well as for 5-HT~2A~ receptors. Compounds (86a), (86b) and (86c) showed antagonistic, partial agonistic and agonistic activity respectively towards 5-HT~1A~ receptors. Compound (86c) (1-{3-(4-(-2-methoxyphenyl)piperazine-1-yl)propyl\]-3^1^,4^1^,-dihydro-2^1^*H*-spiro(imidazoline-4,1^1^-napthalene1-2,5-dione) show agonistic activity towards pre and post synaptic 5-HT2A receptor and evaluated them for antidepressant like effect that is more pronounced in Imipramine on forced swim test in mice without affecting locomotor activity.

Zagorska *et al*.,\[[@ref106]\] synthesized a series of N-8 arylperazinyl-propyl derivatives of 1,3-dimethyl-(1*H*,8*H*)-imidazole\[2, 1-f\]purine-2,4-dione (87). Derivatives were evaluated *in vitro* and found to be potent 5-HT~1A~ receptor ligands. Compound 8\[-3(*N*~4~-phenyl) piperazine-*N*~1~-yl-propyl\]-1,3- dimethyl-(1*H*,8*H*)-imidazo\[2, 1-f\] purine-2,4 dione (87a) exerts anxiolytic-like activity in the four-plate test in mice. Compounds (87a) and 8-\[3-(*N*~4~-2^1^-metoxyphenyl)- piperazine-N-1yl-propyl\]-1,3-dimethyl-(1*H*,8*H*)imidazole-\[2, 1-f\]-purin-2,4-dione (87b) behave like antidepressants in the FST in mice by using imipramine as standard.

Ulak *et al*.,\[[@ref107]\] studied the antidepressant effect and synergistic interaction between 1-(2-trifluoromethylphenyl)-imidazole (TRIM) (88), a novel neuronal nitric oxide synthase (nNOS) inhibitor and conventional antidepressants of different classes and evaluated them in FST in rats. TRIM decreased the immobility time at 50 mg/kg doses.

Rodriguez *et al*.,\[[@ref108]\] studied some potential (bis) guanidine and (bis) 2-aminoimidazoline derivatives. The antidepressant activity of some selected compounds showing pK~i~ value larger than 7 was determined in functional \[35S\]GTPçS binding assays in human brain tissue. *In vivo* activity was determined through microdialysis experiments in rats. They also revealed that the 2-aminoimidazoline derivatives are more potent than the guanidine derivative and have higher affinity. They reported that compounds (89a) and (89b) are most potent for antidepressant activity.

Pyrimidine {#sec1-7}
==========

Pyrimidine and its derivatives attracted great interest due to the wide variety of important pharmacological activities with good pharmacokinetic properties.

Herold *et al*.,\[[@ref109]\] synthesized some analogues of 4-aryl-5, 6, 7, 8-tetrahydropyrido\[1,2-c\]pyrimidine with 3-(1, 2, 3, 6-tetrahydro-pyridin-4-yl)- 1*H*-indole or 2-methyl-3-(1, 2, 3, 6-tetrahydro-pyridin-4-yl)-1H-indole. On the basis of structure activity relationship they concluded that compounds with 3-(1, 2, 3, 6- tetrahydropyridin-4-yl)-1*H*-indole group have higher affinity to the 5-HT~1A~ receptors than the analogous 2-methyl derivatives. Some synthesized compounds (90a), (90b), (90c), (90d), (90e) and (90g) are selective agonists, while (90i) has an antagonistic effect of 5-HT~1A~ on presynaptic receptors in the inducible hypothermia test in mice having Ki value from 28,3 to 642 nM and 42,4 nM - 1,8*μ* M respectively for both 5-HT~1A~ and SERT.

Rodrigues *et al*.,\[[@ref110]\] synthesized 4-(4-chlorophenyl)-6-(4^11^-methylphenyl)-2-hydrazin pyrimidine (91) evaluate.

Herold *et al*.,\[[@ref111]\] synthesized a series of new derivatives of 4-aryl-pyrido\[1,2-c\] pyrimidine (92) containing the 3-(4-piperidyl)-1*H* indole residue or its methoxy derivatives. Presence of -F or -CH~3~ group at ortho or para in aryl ring and the presence of 3-(4-piperidyl)-1*H*-indole residue promoted low K~i~ value for 5-HT~1A~ auto receptors and post-synaptic 5-HT~1A~ receptors. In contrast, the presence of a 5- methoxy -3-(4- piperidyl)-1*H*-indole residue as well as -Cl or -OCH~3~ substituents at the para position markedly reduced the receptor affinity. Compounds (92a), (92b), (92c) showed agonistic effect on post-synaptic 5-HT~1A~ receptor in the FST in mice. Compound (92a) had an effect at 10 mg/kg dose, while compounds (92b), (92c) required higher dose, 20 mg/kg, to be effective.

Herold *et al*.,\[[@ref112]\] synthesized derivatives of 4-aryl-5, 6, 7, 8-tetrahydro-pyrido\[1,2,-c\] pyrimidine (93). These compounds contain the 3-(4 piperidyl)-1-*H* indole residue or its methoxy or 2- methyl derivatives. SAR analysis showed the presence of the 3-(4-piperidyl)-1*H*-indole group or its 5- methoxy derivative as well as a para substitution with -CH~3~(93a) or -F (93b) in the aryl ring of 4-aryl-5, 6, 7, 8 tetrahydro-pyrido\[1,2-c\] pyrimidine results in an affinity for both the 5-HR~1A~ receptor and SERT. The agonistic effects of compounds (93c), (93d), (93e) were demonstrated on post-synaptic 5-HT~1A~ receptors.

Kim *et al*.,\[[@ref113]\] synthesized a series of arylpiperazine-containing pyrimidine 4-carboxamide derivatives. Some synthesized compounds were evaluated for binding affinity to serotonin receptors and transporters. They reported *in vitro* and SAR studies and suggested that compound (94) (IC~50~*μ*M \>10) is the most potent in this series.

Triazole {#sec1-8}
========

Triazole nucleus has planer five-membered heterocyclic system containing three nitrogen atoms, one pyrrole and two pyridine type.\[[@ref114]\] Two structural isomeric forms of triazole are 1,2,3 and 1,2,4.\[[@ref115]\] On the basis of the pharmacological profiles of triazoles, their antidepressant properties seem to be best documented. Nefazodone has triazole nucleus and possesses antidepressant activity. It inhibits the binding of \[*3H*\] ketanserin to cortical serotonin2 (5-HT~2~) binding sites, it antagonizes the 5-HT~2~ and also inhibits cortical serotonin uptake.\[[@ref116]\] Some potent marketed drugs having triazole nucleus are Ribavirin (antiviral), Alprazolam (anxiolytic), Fluconazole, Itraconazole (antifungal) and Rizatriptan (antimigrane). The ambient nucleophilic centers present in triazoles are used for synthesis of various N-bridged heterocycles.\[[@ref117]\]

Kaplancikli *et al*.,\[[@ref118]\] synthesized some triazole-pyrazoline derivatives and investigated their potential antidepressant activity. Antidepressant-like activity of the test compounds (100 mg/Kg)1-\[{4-amino-3-\[2-(4-hydroxyphenyl)ethyl\]-4*H*-1, 2, 4-triazole-5yl)thioacetyl\]-3-(2-thieyl)-5-aryl-2-pyrazoline (95) were screened using both modified forced swimming and tail suspension tests. The test compounds in the series, unsubstituted derivatives (95a) and chlorine-substituted (95b) were more effective than the test compounds (95c), (95d) as compared to reference drug fluoxetine.

Kane *et al*.,\[[@ref119]\] synthesized 5-aryl-2,4-dialkyl-3*H*-1, 2, 4-triazole-3-thiones (96) and evaluated their pharmacological properties.

Varvaresou *et al*.,\[[@ref120]\] synthesized a derivatives of 3-{(2-methyl-1*H*-3-indolyl) methyl)-4-aryl-4,5-dihydro-1*H*-1, 2, 4-triazole-5-thione (97). The antidepressant profile of compounds (97a), (97b) was studied on mice with respect to that of analogue 3-(1*H*-indolylmethyl)-4-aryl-4,5dihydro-1H-1, 2, 4-triazole-5-thione. Compound (97a) was evaluated as a potent antidepressant.

Current perspective {#sec2-3}
-------------------

This review demonstrated that all mentioned heterocyclic moieties and their derivatives have potent antidepressant activity. Additionally, these modifications can be utilized to develop more potentially active agents in order to improve the mental health of the patients.
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